IPSEN (OTCMKTS:IPSEY) Sees Unusually-High Trading Volume – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares saw unusually-high trading volume on Thursday. Approximately 16,248 shares traded hands during trading, an increase of 762% from the previous session’s volume of 1,885 shares. The stock last traded at $40.15 and had previously closed at $39.89.

Analyst Upgrades and Downgrades

IPSEY has been the topic of a number of research analyst reports. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

IPSEN Stock Up 0.7%

The company’s 50 day moving average price is $45.42 and its 200-day moving average price is $46.34.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in specialty care. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with an emphasis on treatments for conditions that often have limited therapeutic options.

The company’s portfolio includes Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected movement disorders and aesthetic applications, and cancer treatments such as Cabometyx and Onivyde.